Therapeutic nanoworms: towards novel synthetic dendritic cells for immunotherapy by Mandal, S. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/120024
 
 
 
Please be advised that this information was generated on 2018-07-07 and may be subject to
change.
Therapeutic nanoworms: towards novel synthetic
dendritic cells for immunotherapy†
Subhra Mandal,‡a Zaskia H. Eksteen-Akeroyd,‡b Monique J. Jacobs,b Roel Hammink,b
Matthieu Koepf,§b Annechien J. A. Lambeck,{a Jan C. M. van Hest,c
Christopher J. Wilson,b Kerstin Blank,*b Carl G. Figdor*a and Alan E. Rowan*b
A new class of antibody-functionalized, semi-ﬂexible and ﬁlamentous polymers (diameter 5–10 nm, length
200 nm) with a controlled persistence length, a high degree of stereoregularity and the potential for
multiple simultaneous receptor interactions has been developed. We have decorated these highly
controlled, semi-stiﬀ polymers with T cell activating anti-CD3 antibodies and analyzed their application
potential as simple synthetic mimics of dendritic cells (sDCs). Our sDCs do not only activate T cells at
signiﬁcantly lower concentrations than free antibodies or rigid sphere-like counterparts (PLGA particles)
but also induce a more robust T cell response. Our novel design further yields sDCs that are
biocompatible and non-toxic. The observed increased eﬃcacy highlights the importance of architectural
ﬂexibility and multivalency for modulating T cell response and cellular function in general.
Introduction
The innate immune system is the body's rst line of defence
against invaders like pathogens and cancerous cells. Among the
various cell types of the innate immune system, dendritic cells
(DCs), also known as “professional” antigen-presenting cells
(APCs) are of prime importance.1 The knowledge about DCs has
increased tremendously in the last 30 years2 and their applica-
bility for cancer immunotherapy has been investigated. Ex vivo
generated DCs, when loaded with tumour lysates, tumour
antigen-derived peptides or whole tumour proteins, have
demonstrated enhanced anti-cancer immune responses.3 Clin-
ical studies have shown the potential of DCs as an autologous
vaccine for cancer immunotherapy.4,5 In spite of their potency,
the application of ex vivo DCs is so far limited by their avail-
ability. Growth of ex vivo DCs is both labour and resource
intensive. The requirement to generate a tailor made vaccine for
every patient6,7 means that ex vivo DCs are not economically
sustainable. The aforementioned ineﬃciencies in the produc-
tion of ex vivo DC's has inspired investigators to design articial
antigen-presenting cells (aAPCs) as alternatives.
Extensive studies onDC/T cell interactions in vitro have shown
that the activation of T cells proceeds via a pre-clustering of
MHC–peptide complexes in microdomains. These micro-
domains subsequently cluster into the so-called ‘immune
synapse’ (IS).8,9 Similar to many extracellular biological recogni-
tion processes, T cell activation consequently requires the
simultaneous multivalent interaction of a number of receptors to
initiate clustering. Molecular constructs that are able to mimic
this simultaneous multivalent binding have a higher eﬃcacy by
increasing the avidity.10–12 Further, activation does not only
involve one type of receptor but instead multiple receptors that
interact with diﬀerent activation inducing molecules (i.e. MHC–
peptides, co-stimulatory adhesion molecules, etc.).
The rst generation of aAPCs, microbead-based DCs, have
shown a marked advantage in expanding specic T cells under
laboratory conditions compared to free MHC–peptide
complexes. Their eﬃcacy for long-term T cell expansion has
been limited, however.13 Unlike aAPCs, natural APCs have the
ability to conform to the cell surface topography and allow the
dynamic movement of receptor–ligand complexes to form the IS
that ultimately causes T cell activation. Most likely the rigid
sphere morphology of these microbead based aAPCs hinders
the eﬃcient formation of multivalent interactions with the
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T cells.14,15 These aAPCs lack the plasma membrane uidity of
natural APCs that allows for the dynamic movement of these
complexes to the IS site.16 So spherical aAPCs, such as lipo-
somes,17 have overcome the membrane uidity constraint
enhancing T cell activation over and above that observed for the
rigid sphere models, suggesting that the IS can form more
eﬃciently if a dynamic movement of both binding partners can
take place (Fig. 1).
Besides an eﬃcient formation of the IS, also the number of
receptor–ligand interactions involved in IS formation is known
to play an important role in T cell activation. The number of
interactions is dictated by the size and the morphology of the
particle. In general, for rigid spherical particles the number of
ligands available to participate in the required simultaneous
interaction is limited by its topology.17–19 Second-generation
immunotherapeutic delivery vehicles have, therefore, explored
extended aspect ratio topologies such as lamentous or rod-like
particles. These extended aspect ratio structures have utilized
either copolymer lomicelles20 or decorated carbon nanotubes
(CNTs).21 Both lomicelles and CNTs have demonstrated a
higher activity compared to their spherical counterparts.21,22
This marked increase in eﬃcacy is most likely a result of the
larger surface-to-volume ratio that allows a more eﬀective
loading. If the micelle area is held constant for a given mass of
co-polymer their eﬀective loading is increased by 50%
compared to the corresponding sphere.20 Besides the increased
eﬀective loading that may aid in enhancing multivalent
binding, lamentous or rod-like particles also show longer
circulation times in the body that might play an additional
advantageous role in T cell activation.20
The design criteria for an ideal synthetic dendritic cell (sDC)
should incorporate the described knowledge gained from
aAPCs and commonly used therapeutic delivery vehicles. It
should combine the above characteristics of a high aspect ratio,
a exible architecture and multiple interactions to achieve
highly eﬃcient T cell activation. The sDCs should further
possess an extended half-life and a low systemic toxicity.23–25
Here, we propose a fundamentally new design of sDCs that
have the potential to full all of the above criteria. Our strategy
to building these novel delivery vehicles is based on a new class
of rod-like, semi-stiﬀ and water-soluble polymers derived from
oligoethylene oxide substituted poly(isocyano peptides).26,27
Poly(isocyano peptides) consist of a helical polyisocyanide
backbone. This backbone carries peptide functionalized side
chains that are attached to every carbon stabilizing the helix
through hydrogen bonding.28–30 These polymers can be up to
2 mm long and exhibit a well-dened stereoregularity31 as well as
a controlled stiﬀness that can be tuned between persistence
lengths (LP) of 5 nm to 200 nm.26,32 Since in principle every
individual monomer can be substituted with a functional unit, a
versatile synthon for the design of multivalent lamentous
sDCs is easily obtained (Fig. 2).
Our hypothesis is that such a semi-stiﬀ poly(isocyano peptide)
decorated with eﬀectormolecules rapidly docks on T cells (Fig. 2a
and b). The semi-stiﬀness of the poly(isocyano peptide) will then
allow all eﬀector molecules on the sDC to bind to neighbouring
receptors on the same cell (Fig. 2c). This is not possible for a rigid
spherical bead or a exible random-coil polymer, where multi-
valent interactions require entropically non-favourable, extended
polymer conformations.10,12 Subsequently, using a semi-stiﬀ
polymer, these receptor sites will be able to cluster with a
concomitant contraction of the polymer backbone to form the IS
while retaining the activated state (Fig. 2d). To test our design
strategy, we functionalized these sDCs with anti-CD3 antibodies
(aCD3–sDC), that are known to cause T cell activation, and
compared their eﬃcacy with microbead based aAPCs (aCD3–
PLGA) and free aCD3 antibodies.
Results and discussion
Synthesis and characterization of the aCD3–sDCs
Synthetic dendritic cells (sDCs) carrying T cell stimulating aCD3
antibodies have been synthesized from semi-stiﬀ poly(isocyano
peptides). To obtain these sDCs, an azide containing poly-
(isocyano peptide) was synthesized in the rst step (see ESI† for
synthetic procedures). This was achieved by co-polymerizing a
mixture of an azide-functionalized monomer and a methoxy-
functionalized monomer using a 1 : 100 molar ratio resulting in
a random copolymer (Scheme 1).
The obtained polymers have a degree of polymerization DP¼
1633 and a length between 150 nm and 200 nm (Table S1†). The
statistical spacing between azide groups is 10 nm. These azide
groups were subsequently used to couple BCN-functionalized
streptavidin (SAv) to the polymer backbone using a strain-
promoted azide alkyne click (SPAAC) reaction.33 The obtained
SAv-functionalized polymer contains on average one SAv mole-
cule every 40–50 nm (Fig. 3), as determined with AFM. sDCs
were obtained by adding biotinylated aCD3 antibodies yielding
aCD3–sDC. When preparing the aCD3–sDC, the ratio of aCD3
to SAv on the polymer was adjusted such that on average every
SAv was bound to one aCD3 antibody (Fig. S6†). Consequently,
an average polymer with a length of 150–200 nm contains
between 3 and 5 aCD3 antibodies.
Cell viability measurements
Before testing the eﬃcacy of these novel sDCs on peripheral
blood lymphocytes (PBLs), cell viability studies were carried outFig. 1 Schematic diagram illustrating diﬀerent systems for T cell activation.
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to study their biocompatibility. PBLs exposed to aCD3–sDC or
free aCD3 at diﬀerent concentrations exhibited no signicant
decrease in cell viability (MTT assay; Fig. 4a). At higher aCD3
concentrations even an increase in the number of cells was
observed, which can be explained by induction of T cell prolif-
eration by the aCD3 antibodies (vide infra). Even aer prolonged
incubation times, cell viability remained constant between 90
and 100% even up to 72 hours (Trypan Blue assay; Fig. 4b).
T cell activation
In subsequent experiments, the capacity of aCD3–sDC to acti-
vate T cells was determined in comparison to free aCD3
antibodies, streptavidin bound aCD3 (aCD3–SAv) and the cor-
responding isotype control (mIgG2a–sDC). Aer clustering of
CD3 on the T cells, intracellular signalling results in direct
activation as demonstrated by expression of the early T cell
activation marker CD69.34 Activated T cells further show
enhanced secretion of IFNg as a late activation event35 and
eventual T cell proliferation is observed.36
At saturating concentrations (>50 ng mL1), CD69 expres-
sion was at its maximum, for both the aCD3–sDC and the
controls including free aCD3 and aCD3–SAv (Fig. 5a). At low
concentrations (1–20 ng mL1), however, the aCD3–sDCs were
2.5 fold more eﬀective in inducing T cell activation when
compared to the aCD3 and aCD3–SAv controls. Similarly, the
Fig. 2 Stages of sDC binding and T cell activation. (a) The mobility of the sDC assists in locating the T cell; (b) sDC docks onto the T cell; (c) attachment to multiple
recognition sites; (d) sDC contracting/clustering at the recognition sites, IS formation.
Scheme 1 Synthetic scheme to obtain streptavidin (SAv) functionalized poly(isocyano peptides). (a) Random co-polymerization of the azide (1) and the methoxy (2)
monomers to obtain the azide-functionalized polymer (3), (i) Ni(Cl2O4)2$6H2O, toluene; (b) coupling of BCN–NHS (4) to SAv, (ii) 4 days at 4 C in 10 mM borate buﬀer
pH 8.5; (c) synthesis of the SAv–polymer bioconjugate (6).
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aCD3–sDC activated T cells released 2–3 fold higher amounts of
IFNg than the tested controls (Fig. 5b). Taken together, these
ndings and the additional controls shown in Fig. S7† indicate
that aCD3–sDC induces a more robust T cell activation when
compared to T cells exposed to free aCD3 or aCD3–SAv.
To substantiate the above ndings, T cell activation was
followed over time at a low eﬀective treatment concentration
(5 ng mL1 aCD3 for both aCD3–sDC and free aCD3). The
aCD3–sDC treated T cells were activated at signicantly earlier
time points (Fig. 5c). Over prolonged exposure, T cell activation
increased up to 35%. In comparison, T cell activation
following treatment with free aCD3 shows a delay in T cell
activation (10 hours vs. 7 hours for aCD3–sDC) and a lower
percentage of activated T cells (only 10–15%). Finally, the
ability of aCD3–sDC to induce T cell proliferation was tested
(50 ng mL1 aCD3 for both aCD3–sDC and free aCD3). In line
with the above results, a 2–3 fold higher number of proliferated
T cells was detected when the T cells were treated with aCD3–
sDC (Fig. 5d). Treatment with aCD3–sDC leads to a constant
increase in the proliferation rate until 72 h of treatment. The
observed decrease in the number of T cells at 96 h is likely
resulting from nutrient depletion in the growth medium at high
cell concentrations.
To investigate the importance of the structural architecture
of our novel sDCs, their eﬃcacy was compared to spherical
aCD3–PLGA particles (1.8 mm diameter, see ESI†). The worm-
like aCD3–sDCs were 7 fold more eﬃcient in stimulating T
cell activation (CD69 expression) when compared to aCD3–
PLGA particles, even at concentrations as low as 1 ng mL1
(Fig. 6a). Also the production of IFNg was 3 fold higher when
compared to aCD3–PLGA particles (Fig. 6b). Together these
observations indicate that our aCD3–sDCs do not only activate
T cells signicantly better at lower concentrations. They also
induce the highest IFNg production when compared with solid
particle based DCs.
This diﬀerence in eﬃcacy cannot be explained with the
number of receptor–ligand interactions that can form when
using aCD3–sDCs (3–5 interactions) or aCD3–PLGA particles
(1–10 interactions; see ESI†). This similar number of possible
interactions for both geometries clearly suggests that it is not
the density of aCD3 but the ability of polymer-based sDCs to
exibly adjust to the spacing of receptors and to dynamically
form the immune synapse that leads to the superior activity of
our sDCs. In other words, multiple static interactions are not
suﬃcient. It has been postulated that a more dynamic aniso-
tropic interaction between the binding partners is required to
induce and enhance T cell activation.37,38 Unlike the static shape
of the hard sphere model, the controlled stiﬀness of the aCD3–
sDC lament has the capacity to ‘concertina’ in response to the
receptor clustering events associated with the formation of the
immune synapse (Fig. 2).
Localization of aCD3–sDC on the cell surface
To investigate the molecular process in more detail and to
understand how the sDCs interact with T cells, binding studies
were performed with uorescently labelled aCD3–sDCs. The
PBLs were incubated with diﬀerent concentrations of either
uorescein labelled aCD3–sDCs (FaCD3–sDC) or free aCD3
(FaCD3) for 24 hours (see ESI†). Subsequently, the number of
uorescent cells was determined using a laser scanning
confocal microscope (Fig. 7 and S9†).
Fig. 3 AFM analysis of polymer 6. (a) Representative AFM image clearly showing the SAv molecules (bright dots) attached to the polymer; (b) number of SAv
molecules per polymer.
Fig. 4 Viability of PBLs exposed to aCD3–sDC. (a) MTTassay showing cell viability
as a function of aCD3 concentration (incubation time 24 h). (b) Trypan Blue assay
showing cell viability as a function of incubation time (aCD3 concentration of
200 ng mL1 for both aCD3–sDC and free aCD3). The results represent the
mean  s.e.m. (n ¼ 3).
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At high concentrations (50 and 100 ng mL1) the relative
number of T cells that show binding of FaCD3–sDC on their
surface was comparable to the percentage of cells that have
been treated with free FaCD3. In the low concentration range
(#20 ng mL1), however, a higher fraction of PBLs carrying
FaCD3–sDC was observed when compared to the cells treated
with free FaCD3. This result clearly explains the higher eﬃcacy
of the aCD3–sDCs in the low concentration range (Fig. 7a).
Fig. 5 T cell activation proﬁle upon treatment at diﬀerent concentrations and after diﬀerent time points. (a) Percentage of T cells showing CD69 expression and (b)
IFNg release at diﬀerent aCD3 concentrations (incubation time 24 h); (c) percentage of Tcells showing CD69 expression after diﬀerent incubation times (aCD3 concentration
5 ng mL1); (d) T cell proliferation estimated using a CFSE assay (aCD3 concentration 50 ng mL1). The values were normalized against the untreated control. Each value
represents the mean  s.e.m. (n ¼ 4). The asterisks (*) indicate the statistical signiﬁcance (*, **, *** p # 0.05, 0.01, 0.001) of aCD3–sDC compared to aCD3.
Fig. 6 Comparison of aCD3–sDC with spherical aCD3–PLGA. (a) Percentage of T cells showing CD69 expression and (b) IFNg release at diﬀerent aCD3 concentrations
(incubation time 24 h); the results represent the mean  s.e.m. (n ¼ 3). The asterisks (*, **, ***p ¼ < 0.05, 0.01, 0.001) indicate the statistical signiﬁcance of aCD3–sDC
compared to aCD3.
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Besides more eﬃcient binding, 3D images taken aer 24 hours
further reveal that FaCD3–sDC remained co-localized on the
membrane indicating that no receptor internalization has been
taking place (Fig. 7b).
Summarizing the above results, this new class of semi-stiﬀ
and lamentous polymers serves as an ideal scaﬀold for func-
tionalization with antibodies to allow for multiple, simulta-
neous receptor interactions. These novel sDCs do not only
activate T cells at signicantly lower concentrations than free
antibodies and their rigid sphere-like PLGA counterparts but
also induce a faster T cell response. Docking of the rst anti-
body to the T cell increases the eﬀective molarity of aCD3 at the
cell surface thereby increasing the probability for the remaining
antibodies to bind (Fig. 2b). It is known that T cell stimulation
by aCD3 in solution causes internalization of the CD3 leading to
termination of the T cell response.39 The experiments with
uorescently labelled FaCD3–sDC have indicated that FaCD3–
sDC remains bound on the T cell surface even aer 24 h of
treatment. The semi-stiﬀ, lamentous morphology of the
aCD3–sDCs consequently does not only lead to a signicantly
higher and earlier (CD69 expression) but also to a more sus-
tained T cell response compared to the free antibody and the
spherical geometry. This result is supported by the expression
of the late stage activation marker INFg and the associated
higher T cell proliferation rates. These ndings have important
consequences for the therapeutic use of aCD3 antibodies,
which show in vivo toxicity at high concentrations.40 As our
aCD3–sDCs show T cell activation at lower concentrations
compared to free aCD3 antibodies, this new design can help to
overcome these toxicity problems and widen the therapeutic
window of aCD3 antibodies.
Despite their clearly proven potential as a DC mimic, a
number of open questions remain. The stiﬀness of the polymer
combined with the density of eﬀector molecules appears to be
the crucial parameter for eﬃcient T cell activation. Antibody-
functionalized poly(isocyano peptides) are an ideal scaﬀold to
investigate the importance of these parameters in a systematic
way. Both the density of eﬀector molecules as well as the poly-
mer stiﬀness can be easily tuned for this new class of functional
polymers. Experiments are currently underway to study the role
of the polymer length, the polymer stiﬀness and the eﬀector
molecule loading on T cell activation.
Conclusions
In this report we demonstrate that multivalency in combination
with a controlled semi-stiﬀness are key parameters for
designing potentially therapeutically active vehicles that closely
mimic natural DCs. Using our novel sDC design, we observe a
more eﬃcient as well as more sustained T cell response. This
enhanced activity clearly validates the nal stage of the
proposed binding mechanism (Fig. 2d) that requires the sDC to
respond to the processes occurring on the T cell surface during
formation of the immune synapse. Having shown the potency of
our sDCs, our next goal is a more detailed investigation of the
sDC induced T cell activation mechanism. This will ultimately
allow us to increase their eﬃcacy even further. To develop the
presented sDC system for clinical applications against cancer,
the aCD3 antibodies will be replaced with MHC–peptide
complexes and co-stimulatory molecules, necessary for highly
eﬃcient T cell activation. Cytokines can be coupled in addition
to further shape the T cell response. Ultimately, aer charac-
terization of their in vivo behaviour, our sDCs have the potential
to become a highly eﬃcient and cost-eﬀective nanovaccine for
cancer immunotherapy. Besides cancer immunotherapy, the
semi-stiﬀ poly(isocyano peptides) scaﬀold might be used for
other applications where multivalent binding is essential.
Multivalency, for example, plays an important role in drug tar-
geting. Functionalization of the scaﬀold with eﬀector molecules
as well as targeting and imaging moieties can potentially lead to
a more eﬃcient accumulation and detection of the therapeutic
agent at the desired site of action opening up a far bigger range
of possible therapeutic and diagnostic applications.
Fig. 7 aCD3–sDC binding and location on the cell. (a) percentage of PBLs
showing bound FaCD3 or FaCD3–sDC after 24 hours of treatment. The result
shows the mean  s.e.m. (n ¼ 3). The signiﬁcance of aCD3–sDC compared to
aCD3 is indicated by the asterisks (***p # 0.001). (b) Orthographic projection of
one PBL illustrating aCD3–sDC clustering/binding (yellow; co-localization of red
and green ﬂuorescence). The ﬂuorescence image is merged with a DIC image. The
series shows optical cross sections over the y-coordinate (x- and z-coordinate
constant), demonstrating the aCD3–sDC distribution on the cell.
This journal is ª The Royal Society of Chemistry 2013 Chem. Sci., 2013, 4, 4168–4174 | 4173
Edge Article Chemical Science
Pu
bl
ish
ed
 o
n 
02
 A
ug
us
t 2
01
3.
 D
ow
nl
oa
de
d 
by
 R
ad
bo
ud
 U
ni
ve
rs
ite
it 
N
ijm
eg
en
 on
 09
/01
/20
18
 08
:07
:13
. 
View Article Online
Acknowledgements
This work was supported by grants from the Dutch Cancer
Society (grants KUN2006-3699 and KUN2009-4402), the Dutch
government to the Netherlands Institute for Regenerative
Medicine (NIRM, grant FES0908), the European Research
Council (ERC; grant ERC-2010-AdG269019, C.G.F.), the Neth-
erlands Organization for Scientic Research (NWO; Spinoza
award 2006, C.G.F; VICI grant 700.56.444, A.E.R.; VIDI grant
700.58.430, K.B.), the Foundation for Fundamental Research on
Matter (FOM; grant 10PR2791) as well as NanoNext (grants
7A.06 and 3D.12).
References
1 J. Banchereau and R. M. Steinman, Nature, 1998, 392, 245–
252.
2 R. M. Steinman and Z. A. Cohn, J. Exp. Med., 1973, 137, 1142–
1162.
3 L. Fong and E. G. Engleman, Annu. Rev. Immunol., 2000, 18,
245–273.
4 A. Ballestrero, D. Boy, E. Moran, G. Cirmena, P. Brossart and
A. Nencioni, Adv. Drug Delivery Rev., 2008, 60, 173–183.
5 I. Houtenbos, T. M.Westers, G. J. Ossenkoppele and A. A. van
de Loosdrecht, Immunobiology, 2006, 211, 677–685.
6 M. Oelke, C. Krueger, R. L. Giuntoli and J. P. Schneck, Trends
Mol. Med., 2005, 11, 412–420.
7 W. Gong, M. Ji, Z. Cao, L. Wang, Y. Qian, M. Hu, L. Qian and
X. Pan, Cell. Mol. Immunol., 2008, 5, 47–53.
8 F. Giannoni, J. Barnett, K. Bi, R. Samodal, P. Lanza,
P. Marchese, R. Billetta, R. Vita, M. R. Klein, B. Prakken,
W. W. Kwok, E. Sercarz, A. Altman and S. Alban, J.
Immunol., 2005, 174, 3204–3211.
9 M. L. Dustin, Immunity, 2004, 21, 305–314.
10 S. Liu and K. L. Kiick, Macromolecules, 2008, 41, 764–772.
11 S. Liu, R. Maheshwari and K. L. Kiick,Macromolecules, 2009,
42, 3–13.
12 C. Fasting, C. A. Schalley, M. Weber, O. Seitz, S. Hecht,
B. Koksch, J. Dernedde, C. Graf, E. W. Knapp and R. Haag,
Angew. Chem., Int. Ed., 2012, 51, 10472–10498.
13 I. Laux, A. Khoshnan, C. Tindell, D. Bae, X. Zhu, C. H. June,
R. B. Eﬀros and A. Nel, Clin. Immunol., 2000, 96, 187–197.
14 H. A. Anderson, E. M. Hiltbold and P. A. Roche, Nat.
Immunol., 2000, 1, 156–162.
15 A. B. Vogt, S. Spindeldreher and H. Kropshofer, Immunol.
Rev., 2002, 189, 136–151.
16 B. Prakken, M. Wauben, D. Genini, R. Samodal, J. Barnett,
A. Mendivil, L. Leoni and S. Albani, Nat. Med., 2000, 6,
1406–1410.
17 R. Zappasodi, M. Di Nicola, C. Carlo-Stella, R. Mortarini,
A. Molla, C. Vegetti, S. Albani, A. Anichini and
A. M. Gianni, Haematologica, 2008, 93, 1523–1534.
18 E. Koﬀeman, E. Keogh, M. Klein, B. Prakken and S. Albani,
Methods Mol. Med., 2007, 136, 69–86.
19 C. Schu¨tz, M. Oelke, J. P. Schneck, A. Mackensen and
M. Fleck, Immunotherapy, 2010, 2, 539–550.
20 S. Cai, K. Vijayan, D. Cheng, E. M. Lima and D. E. Discher,
Pharm. Res., 2007, 24, 2099–2109.
21 T. R. Fadel, E. R. Steenblock, E. Stern, N. Li, X. Wang,
G. L. Haller, L. D. Pfeﬀerle and T. M. Fahmy, Nano Lett.,
2008, 8, 2070–2076.
22 Y. Geng, P. Dalhaimer, S. Cai, R. Tsai, M. Tewari, T. Minko
and D. E. Discher, Nat. Nanotechnol., 2007, 2, 249–255.
23 E. Heister, V. Neves, C. Tˆılmaciu, K. Lipert, V. S. Beltra,
H. M. Coley, S. R. P. Silva and J. McFadden, Carbon, 2009,
47, 2152–2160.
24 K. Rajagopal, D. A. Christian, T. Harada, A. Tian and
D. E. Discher, Int. J. Polym. Sci., 2010, 379286.
25 V. V. Shuvaev, M. A. Ilies, E. Simone, S. Zaitsev, Y. Kim,
S. Cai, A. Mahmud, T. Dziubla, S. Muro, D. E. Discher and
V. R. Muzykantov, ACS Nano, 2011, 5, 6991–6999.
26 P. H. J. Kouwer, M. Koepf, V. A. A. Le Sage, M. Jaspers,
A. M. van Buul, Z. H. Eksteen-Akeroyd, T. Woltinge,
E. Schwartz, H. J. Kitto, R. Hoogenboom, S. J. Picken,
R. J. M. Nolte, E. Mendes and A. E. Rowan, Nature, 2013,
493, 651–655.
27 M. Koepf, H. J. Kitto, E. Schwartz, P. H. J. Kouwer,
R. J. M. Nolte and A. E. Rowan, Eur. Polym. J., 2013, 49, 1510.
28 H. G. J. Visser, R. J. M. Nolte andW. Drenth,Macromolecules,
1985, 18, 1818–1825.
29 J. M. van der Eijk, R. J. M. Nolte, W. Drenth and
A. M. F. Hezemans, Macromolecules, 1980, 13, 1391–1397.
30 J. J. Cornelissen, J. J. Donners, R. de Gelder,
W. S. Graswinckel, G. A. Metselaar, A. E. Rowan,
N. A. Sommerdijk and R. J. M. Nolte, Science, 2001, 293,
676–680.
31 Z. Q. Wu, K. Nagai, M. Banno, K. Okoshi, K. Onitsuka and
E. Yashima, J. Am. Chem. Soc., 2009, 131, 6708–6718.
32 A. M. van Buul, E. Schwartz, P. Brocorens, M. Koepf,
D. Beljonne, J. C. Maan, P. C. M. Christianen,
P. H. J. Kouwer, R. J. M. Nolte, H. Engelkamp, K. Blank
and A. E. Rowan, Chem. Sci., 2013, 4, 2357–2363.
33 J. Dommerholt, S. Schmidt, R. Temming, L. J. A. Hendriks,
F. P. J. T. Rutjes, J. C. M. van Hest, D. J. Lefeber, P. Friedl
and F. L. van Del, Angew. Chem., Int. Ed., 2010, 49, 9422–
9425.
34 I. Yamashita, T. Nagata, T. Tada and T. Nakayama, Int.
Immunol., 1993, 5, 1139–1150.
35 M. Murphy, R. Loudon, M. Kobayashi and G. Trinchieri, J.
Exp. Med., 1986, 164, 263–279.
36 J. E. Kay, Immunol. Lett., 1991, 29, 51–54.
37 E. D. Zanders, J. R. Lamb, M. Feldmann, N. Green and
P. C. L. Beverley, Nature, 1983, 303, 625–627.
38 S. C. Balmert and S. R. Little, Adv. Mater., 2012, 24, 3757–
3778.
39 C. Calabia-Linares, J. Robles-Valero, H. de la Fuente,
M. Perez-Martinez, N. Martin-Cofreces, M. Alfonso-Perez,
C. Gutierrez-Vazquez, M. Mittelbrunn, S. Ibiza,
F. R. Urbano-Olmos, C. Aguado-Ballano, C. O. Sanchez-
Sorzano, F. Sanchez-Madrid and E. Veiga, J. Cell Sci., 2011,
124, 820–830.
40 J. D. Ellenhorn, R. Hirsch, H. Schreiber and J. A. Bluestone,
Science, 1988, 242, 569–571.
4174 | Chem. Sci., 2013, 4, 4168–4174 This journal is ª The Royal Society of Chemistry 2013
Chemical Science Edge Article
Pu
bl
ish
ed
 o
n 
02
 A
ug
us
t 2
01
3.
 D
ow
nl
oa
de
d 
by
 R
ad
bo
ud
 U
ni
ve
rs
ite
it 
N
ijm
eg
en
 on
 09
/01
/20
18
 08
:07
:13
. 
View Article Online
